Asset Details
Do you wish to reserve the book?
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Do you wish to request the book?
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
2014
Overview
This study shows that in postmenopausal women with low bone mineral density, the monoclonal antibody romosozumab, which binds to sclerostin, an osteoblast-activity inhibitor, was associated with increased bone mineral density and bone formation and decreased bone resorption.
Osteoporosis is characterized by low bone mass and defects in microarchitecture that are responsible for decreased bone strength and increased risk of fracture.
1
Antiresorptive drugs for osteoporosis increase bone mineral density and prevent the progression of structural damage but may not restore bone structure. Stimulation of bone formation is necessary to achieve improvements in bone mass, architecture, and strength.
Sclerostin, encoded by the gene
SOST,
is an osteocyte-secreted glycoprotein that has been identified as a pivotal regulator of bone formation. By inhibiting the Wnt and bone morphogenetic protein signaling pathways, sclerostin impedes osteoblast proliferation and function, thereby decreasing bone formation. . . .
Publisher
Massachusetts Medical Society
Subject
/ Alendronate - therapeutic use
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - pharmacology
/ Bone Density Conservation Agents - administration & dosage
/ Bone Density Conservation Agents - adverse effects
/ Bone Density Conservation Agents - pharmacology
/ Bone Remodeling - drug effects
/ Drug Administration Schedule
/ Female
/ Femur
/ Hip
/ Humans
/ Lumbar Vertebrae - drug effects
/ Osteoporosis, Postmenopausal - drug therapy
